A Phase IIIb, Randomized, Multicenter, Open-label Study To Assess The Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab In Combination With Platinum-Based Chemotherapy For First-Line Treat

Activity Type
Clinical Trial
Date
Dollar Amount
*
Grant Type
Contract
Principal Investigator
Linda Garland
Sponsor
Astrazeneca
Unit
Cancer Center Division